Liz Highleyman

Pairing HCV testing and treatment eliminates the need to navigate the medical system.

The PreHevbrio vaccine produces higher antibody levels and offers faster protection.

Early vaccination reduces the risk of cervical cancer by nearly 90%, but many young people remain unprotected.

Experts recommend no more than two drinks for men or one drink for women per day.

Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.

Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.

Every-other-month cabotegravir injections may work even better than daily pills for HIV prevention.

FDA authorizes Evusheld for immunocompromised people who may not respond well to COVID-19 vaccines.

Even with this increase, older individuals now have better transplant outcomes.

Older and immunocompromised people and those with underlying health conditions could benefit most from additional shots.

Now that the dam has broken, it may not be long before additional overdose prevention centers open around the country.

Black and Latino men who have sex with men are not seeing the same improvements as white men, but innovative approaches can help.

Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.

While a majority of people with HIV worldwide achieve an undetectable viral load, it may not be durable over time.

Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.